methadone has been researched along with Neoplasms in 223 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways." | 9.41 | Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023) |
| "This study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone." | 9.17 | Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. ( Lauretti, GR; Mattos, AL; Rizzo, CC; Rodrigues, SW, 2013) |
| "To compare the effectiveness and side effects of methadone and morphine as first-line treatment with opioids for cancer pain." | 9.11 | Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. ( Bertolino, M; Bosnjak, S; Bruera, E; Fisch, MJ; Mathias, C; Moyano, J; Palmer, JL; Rico, MA; Spruyt, O; Strasser, F; Sweeney, C; Willey, J, 2004) |
| "Methadone is effective for chronic cancer pain, but its early pharmacodynamic profile and effectiveness for breakthrough pain remain uncertain." | 9.11 | Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. ( Fisher, K; Hagen, NA; Stiles, C, 2004) |
| "Methadone is a strong opioid analgesic that has been used successfully in cancer pain management." | 9.11 | Intermittent subcutaneous methadone administration in the management of cancer pain. ( Centeno, C; Vara, F, 2005) |
| "This prospective study documents the use of methadone as part of an opioid rotation strategy in patients with uncontrolled pain and severe delirium admitted for terminal care to a tertiary cancer palliative care hospital." | 9.11 | Methadone in the treatment of pain and terminal delirum in advanced cancer patients. ( Comfort, C; Kogan, M; Moryl, N; Obbens, E, 2005) |
| "The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies." | 9.10 | Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002) |
| "To assess the use of methadone in patients with cancer pain who fail to respond to increasing doses of other opioids or experience intolerable side-effects from them." | 9.09 | Methadone titration in opioid-resistant cancer pain. ( Gonty, N; Scholes, CF; Trotman, IF, 1999) |
| "In a prospective, open study, 37 advanced cancer patients in poor pain control receiving high doses of subcutaneous hydromorphone (mean daily dose: 276 +/- 163 mg) were switched to methadone by use of custom-made capsules (21 patients) or suppositories (16 patients)." | 9.08 | Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. ( Bruera, E; Fainsinger, RL; Inturrisi, C; Spachynski, K; Suarez-Almazor, M; Watanabe, S, 1995) |
| "Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect." | 9.08 | Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. ( Caligara, M; Mercadante, S; Sapio, M; Serretta, R, 1996) |
| "To determine the relationship between changes in plasma methadone concentration and pharmacodynamic effects, plasma methadone profiles and pharmacodynamics (analgesia and sedation) were measured during and after the continuous infusion of methadone for 180 to 270 minutes in 15 patients with pain caused by cancer." | 9.06 | Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. ( Colburn, WA; Foley, KM; Inturrisi, CE; Max, MB; Portenoy, RK, 1990) |
| "Eighteen patients suffering from cancer were entered into a study of the pharmacokinetics and efficacy of methadone and morphine in pain control." | 9.06 | A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ( Cherry, DA; Cousins, MJ; Gourlay, GK, 1986) |
| "Methadone is a valuable opioid in the management of patients who have cancer with pain." | 8.98 | Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer. ( Costantino, RC; McPherson, AL; McPherson, ML, 2018) |
| "To determine the effectiveness and tolerability of methadone as an analgesic in adults and children with cancer pain." | 8.95 | Methadone for cancer pain. ( Derry, S; Nicholson, AB; Watson, GR; Wiffen, PJ, 2017) |
| "The proven therapeutic efficacy of methadone in cancer pain is hindered by a challenging pharmacokinetic-pharmacodynamic profile, considerable interpatient variation, and increasing concern about the complexities of dosing." | 8.90 | Therapeutic challenges in cancer pain management: a systematic review of methadone. ( Afsharimani, B; Good, P; Hardy, J; Haywood, A; Khan, S; Movva, R, 2014) |
| "To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain." | 8.89 | Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013) |
| "To outline pharmacodynamics, pharmacokinetics, drug interactions, equianalgesic dose ratio with other opioids, dosing rules, adverse effects and methadone clinical studies in patients with cancer pain." | 8.85 | The role of methadone in cancer pain treatment--a review. ( Leppert, W, 2009) |
| "Methadone is an opioid used in the management of cancer pain." | 8.84 | Methadone for cancer pain. ( Nicholson, AB, 2007) |
| "Methadone is an opioid used in the management of cancer pain both in opioid naïve patients and in rotation from other opioids." | 8.82 | Methadone for cancer pain. ( Nicholson, AB, 2004) |
| " Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]." | 8.81 | The use of methadone for cancer pain. ( Bianchi, M; Ripamonti, C, 2002) |
| "Methadone, a synthetic opioid, has unique pharmacodynamics and pharmacokinetics, which contribute to its unique ability to relieve pain unresponsive to other potent opiates and its unique dosing and drug interactions." | 8.81 | Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. ( Davis, MP; Walsh, D, 2001) |
| "In recent years a better understanding of the pharmacologic and pharmacokinetic properties of methadone, including equianalgesic ratios has led to its increased use as a second line opioid for the treatment of pain in patients with cancer." | 8.81 | Methadone use in cancer patients with pain: a review. ( Bruera, E; Sweeney, C, 2002) |
| "Methadone is commonly considered an alternative opioid treatment for refractory cancer pain." | 8.12 | Methadone switching for refractory cancer pain. ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2022) |
| "Methadone is a useful option in the treatment of cancer pain." | 8.12 | Methadone rotation for cancer pain: an observational study. ( Hum, A; Tan, C; Wong, JF; Yee, CM, 2022) |
| "The prevalence of poisoning from methadone and prescription opioids is increasing in pediatric populations." | 8.02 | A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children. ( Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N, 2021) |
| "To describe the titration phase of the treatment with low-dose first-line methadone and the use of methadone for breakthrough pain." | 8.02 | First-line methadone for cancer pain: titration time analysis. ( Armesto, A; Bertolino, M; Bruera, E; Bunge, S; Dran, G; Mammana, G; Orellana, F; Peirano, G; Vega, F, 2021) |
| "Although methadone has the potential to improve the management of cancer pain, it has some serious problems, such as respiratory depression and QT interval prolongation." | 8.02 | Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting. ( Matsuda, Y; Okayama, S, 2021) |
| "The use of methadone for cancer pain is limited by the need of expertise and close titration due to variable half-life." | 7.83 | Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit. ( Armesto, A; Bertolino, MS; Camerano, G; Dran, G; Mammana, GP; Pastrana, T; Peirano, GP; Ruggiero, R; Russo, J; Varela, G; Vega, GF; Vignaroli, E, 2016) |
| "Previous research has reported improved pain after adding methadone to another opioid, but did not quantify this benefit using a validated outcome measure." | 7.79 | Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. ( Bryson, J; Mak, E; Ridley, J; Wallace, E; Zimmermann, C, 2013) |
| "Methadone is an effective and inexpensive opioid for cancer pain treatment." | 7.76 | Methadone initiation and rotation in the outpatient setting for patients with cancer pain. ( Bruera, E; Calderon, B; de la Cruz, M; El Osta, B; Li, Z; Palmer, JL; Parsons, HA, 2010) |
| "We conducted a feasibility study of sublingual methadone for breakthrough cancer pain, to determine whether a larger, randomized trial was warranted, and to identify a study design that would be likely to succeed." | 7.76 | A formal feasibility study of sublingual methadone for breakthrough cancer pain. ( Biondo, PD; Brasher, PM; Eliasziw, M; Hagen, NA; Moulin, DE; Stiles, CR; Watanabe, SM, 2010) |
| "Racemic methadone is increasingly used to manage cancer pain." | 7.73 | Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ( Auret, K; Boyd, F; Ilett, KF; Oh, TE; Page-Sharp, M; Roger Goucke, C, 2006) |
| "An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain." | 7.71 | Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001) |
| "Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids." | 7.70 | Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. ( Bruera, ED; Hanson, J; Lawlor, PG; Turner, KS, 1998) |
| "Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain." | 7.70 | Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. ( Belzile, M; Bruera, E; De Conno, F; Groff, L; Hanson, J; Pereira, J; Ripamonti, C, 1998) |
| "To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone." | 7.70 | Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? ( Brunelli, C; De Conno, F; Groff, L; Polastri, D; Ripamonti, C; Stavrakis, A, 1998) |
| " In the past 2 years, oral methadone has been used extensively in our institution for treating children with persistent pain from cancer, burns, or trauma who were capable of oral intake and whose pain was not relieved by nonopioid medications." | 7.70 | Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases. ( Davidson, EM; Rosen, G; Shavelson, V; Shenkman, Z; Shir, Y, 1998) |
| "The aims of this study were to describe the analgesia, side effects, and dosage and the causes of suspension of treatment in a large sample of advanced cancer patients with pain after treatment with oral methadone from 7 to 90 days." | 7.69 | Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. ( Brunelli, C; De Conno, F; Groff, L; Ripamonti, C; Ventafridda, V; Zecca, E, 1996) |
| " Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3." | 6.82 | Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016) |
| "Forty-two cancer patients with pain and/or opioid side effects were assessed in this randomised trial." | 6.77 | Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. ( Dale, O; Kaasa, S; Moksnes, K; Paulsen, Ø; Rosland, JH; Spigset, O, 2012) |
| " After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)." | 6.68 | Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997) |
| "Up to 44% of patients with cancer-related pain require opioid rotation (OR) because of inadequate analgesia or side effects." | 6.52 | Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. ( McLean, S; Twomey, F, 2015) |
| "Methadone was used subcutaneously as an analgesic agent in 1 patient." | 6.47 | Review of cancer pain management in patients receiving maintenance methadone therapy. ( McLean, S; McQuillan, R; O'Gorman, A; Rowley, D; Ryan, K, 2011) |
| "Ongoing assessment, multiple approaches, and excellent communication among all care management team members are critical." | 6.43 | Difficult cases in pain management: use of methadone in a multifactorial approach. ( Coyle, N; Coyne, P; Griffie, J, 2006) |
| "Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition." | 6.43 | Methadone for treatment of cancer pain. ( Bryson, J; Seccareccia, D; Tamber, A; Zimmermann, C, 2006) |
| "Methadone is a synthetic opioid, with mu and delta receptor activity, associated with the capacity to inhibit N-methyl-D-aspartate receptors." | 6.41 | Opioid switch to oral methadone in cancer pain. ( Body, JJ; Lossignol, DA; Mancini, I, 2000) |
| "Trigeminal neuralgia (TN) secondary to malignancy leads to significant distress and subsequently impacts a patient's quality of life." | 5.91 | Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report. ( Akel, R; Bromberg, H; Craig, D; Guastella, A; Haas, M, 2023) |
| "Methadone doses were changed according to the clinical needs to obtain the most favorable balance between analgesia and adverse effects." | 5.72 | Methadone as First-line Opioid for the Management of Cancer Pain. ( Adile, C; Bonanno, G; Casuccio, A; Ferrera, P; Mercadante, S; Pallotti, MC; Ricci, M, 2022) |
| " An individualized approach to dosage and route should be considered based on specific clinical circumstances." | 5.62 | Methadone for Cancer Pain in Pediatric End-of-Life Care. ( Anghelescu, DL; Habashy, C; Hall, EA; Sauer, HE, 2021) |
| "Methadone can cause a prolonged QTc interval that can lead to ventricular arrhythmias." | 5.46 | The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain. ( Bruera, E; Liu, D; Madden, K; Park, M, 2017) |
| "Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways." | 5.41 | Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023) |
| "Methadone is a synthetic opioid with excellent oral bioavailability, variable, but long duration of action and extremely low cost." | 5.29 | Respiratory depression in a patient receiving oral methadone for cancer pain. ( Bruera, E; Hunt, G, 1995) |
| "Methadone is a potent analgesic used to treat refractory cancer pain." | 5.24 | Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer? ( George, R; Good, P; Hardy, J; Haywood, A; Hennig, S; Khan, S; Norris, R, 2017) |
| "This study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone." | 5.17 | Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. ( Lauretti, GR; Mattos, AL; Rizzo, CC; Rodrigues, SW, 2013) |
| "Data on the treatment of breakthrough cancer pain (BTcP) in patients receiving methadone therapy are lacking." | 5.15 | The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. ( Arcuri, E; Ferrera, P; Mercadante, S, 2011) |
| "The SAG patients reported a trend of more pain, had significantly more dropouts and three SAEs, which indicate that the SAG strategy should not replace the 3DS when switching from high doses of morphine or oxycodone to methadone." | 5.15 | How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. ( Dale, O; Kaasa, S; Klepstad, P; Moksnes, K; Paulsen, O; Rosland, JH, 2011) |
| "Methadone was administered to 21 opioid-tolerant cancer patients because of pain (numerical rating scale [NRS] > 5) on morphine (ten patients), transdermal fentanyl (TF; four patients), morphine, ketamine, and TF (one patient), tramadol (one patient), pethidine (one patient), pain with drowsiness on morphine with ketamine (three patients), and pain with nausea on morphine (one patient)." | 5.14 | The role of methadone in opioid rotation-a Polish experience. ( Leppert, W, 2009) |
| "This study aims to evaluate the efficacy of methadone as substitute for morphine and to investigate if the addition of acetaminophen could reduce the time to attain an equianalgesic dose of methadone and/or to improve the level of pain control in oncologic patients." | 5.14 | Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. ( Cubero, DI; del Giglio, A, 2010) |
| "The purpose of this study was to determine the effect of initiation of methadone on QTc interval in patients with cancer pain seen at the palliative care setting." | 5.14 | The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. ( Bruera, E; de la Cruz, M; El Osta, B; Hui, D; Palmer, JL; Reddy, S; Walker, P, 2010) |
| "To compare the effectiveness and side effects of methadone and morphine as first-line treatment with opioids for cancer pain." | 5.11 | Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. ( Bertolino, M; Bosnjak, S; Bruera, E; Fisch, MJ; Mathias, C; Moyano, J; Palmer, JL; Rico, MA; Spruyt, O; Strasser, F; Sweeney, C; Willey, J, 2004) |
| "Methadone is effective for chronic cancer pain, but its early pharmacodynamic profile and effectiveness for breakthrough pain remain uncertain." | 5.11 | Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. ( Fisher, K; Hagen, NA; Stiles, C, 2004) |
| "Methadone is a strong opioid analgesic that has been used successfully in cancer pain management." | 5.11 | Intermittent subcutaneous methadone administration in the management of cancer pain. ( Centeno, C; Vara, F, 2005) |
| "This prospective study documents the use of methadone as part of an opioid rotation strategy in patients with uncontrolled pain and severe delirium admitted for terminal care to a tertiary cancer palliative care hospital." | 5.11 | Methadone in the treatment of pain and terminal delirum in advanced cancer patients. ( Comfort, C; Kogan, M; Moryl, N; Obbens, E, 2005) |
| "The successful use of methadone in cancer pain has been supported by numerous case reports and clinical studies." | 5.10 | Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. ( Derby, S; Fischberg, D; Kornick, C; Manfredi, PL; Moryl, N; Payne, R; Santiago-Palma, J, 2002) |
| "To assess the use of methadone in patients with cancer pain who fail to respond to increasing doses of other opioids or experience intolerable side-effects from them." | 5.09 | Methadone titration in opioid-resistant cancer pain. ( Gonty, N; Scholes, CF; Trotman, IF, 1999) |
| "Fifty-two consecutive cancer patients receiving oral morphine but with uncontrolled pain and/or moderate to severe opioid adverse effects were switched to oral methadone administered every 8 hours using different dose ratios." | 5.09 | Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. ( Boffi, R; Casuccio, A; Fulfaro, F; Gebbia, V; Groff, L; Mercadante, S; Ripamonti, C; Villari, P, 2001) |
| "In a prospective, open study, 37 advanced cancer patients in poor pain control receiving high doses of subcutaneous hydromorphone (mean daily dose: 276 +/- 163 mg) were switched to methadone by use of custom-made capsules (21 patients) or suppositories (16 patients)." | 5.08 | Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. ( Bruera, E; Fainsinger, RL; Inturrisi, C; Spachynski, K; Suarez-Almazor, M; Watanabe, S, 1995) |
| "Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect." | 5.08 | Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. ( Caligara, M; Mercadante, S; Sapio, M; Serretta, R, 1996) |
| "To determine the relationship between changes in plasma methadone concentration and pharmacodynamic effects, plasma methadone profiles and pharmacodynamics (analgesia and sedation) were measured during and after the continuous infusion of methadone for 180 to 270 minutes in 15 patients with pain caused by cancer." | 5.06 | Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. ( Colburn, WA; Foley, KM; Inturrisi, CE; Max, MB; Portenoy, RK, 1990) |
| "Eighteen patients suffering from cancer were entered into a study of the pharmacokinetics and efficacy of methadone and morphine in pain control." | 5.06 | A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. ( Cherry, DA; Cousins, MJ; Gourlay, GK, 1986) |
| "Methadone is a valuable opioid in the management of patients who have cancer with pain." | 4.98 | Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer. ( Costantino, RC; McPherson, AL; McPherson, ML, 2018) |
| "To determine the effectiveness and tolerability of methadone as an analgesic in adults and children with cancer pain." | 4.95 | Methadone for cancer pain. ( Derry, S; Nicholson, AB; Watson, GR; Wiffen, PJ, 2017) |
| "The proven therapeutic efficacy of methadone in cancer pain is hindered by a challenging pharmacokinetic-pharmacodynamic profile, considerable interpatient variation, and increasing concern about the complexities of dosing." | 4.90 | Therapeutic challenges in cancer pain management: a systematic review of methadone. ( Afsharimani, B; Good, P; Hardy, J; Haywood, A; Khan, S; Movva, R, 2014) |
| "To determine the analgesic efficacy of transdermal fentanyl for relief of cancer pain, and to assess the adverse events associated with the use of transdermal fentanyl for relief of cancer pain." | 4.89 | Transdermal fentanyl for cancer pain. ( Derry, S; Hadley, G; Moore, RA; Wiffen, PJ, 2013) |
| "To summarize the unique characteristics of methadone and the putative mechanisms of rapid-onset opioid formulations for breakthrough pain; to outline the principles underlying opioid rotation; and to describe elements of risk assessment in opioid therapy." | 4.85 | Clinical approaches to special issues related to opioid therapy. ( Fine, PG, 2009) |
| "To outline pharmacodynamics, pharmacokinetics, drug interactions, equianalgesic dose ratio with other opioids, dosing rules, adverse effects and methadone clinical studies in patients with cancer pain." | 4.85 | The role of methadone in cancer pain treatment--a review. ( Leppert, W, 2009) |
| "Methadone is an opioid used in the management of cancer pain." | 4.84 | Methadone for cancer pain. ( Nicholson, AB, 2007) |
| " Evidence presented in this review shows encouraging results following the administration of methadone, fentanyl or ketamine to patients with difficult pain problems." | 4.82 | Morphine is not the only analgesic in palliative care: literature review. ( Wootton, M, 2004) |
| "Methadone is an opioid used in the management of cancer pain both in opioid naïve patients and in rotation from other opioids." | 4.82 | Methadone for cancer pain. ( Nicholson, AB, 2004) |
| " Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]." | 4.81 | The use of methadone for cancer pain. ( Bianchi, M; Ripamonti, C, 2002) |
| "Methadone, a synthetic opioid, has unique pharmacodynamics and pharmacokinetics, which contribute to its unique ability to relieve pain unresponsive to other potent opiates and its unique dosing and drug interactions." | 4.81 | Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. ( Davis, MP; Walsh, D, 2001) |
| "In recent years a better understanding of the pharmacologic and pharmacokinetic properties of methadone, including equianalgesic ratios has led to its increased use as a second line opioid for the treatment of pain in patients with cancer." | 4.81 | Methadone use in cancer patients with pain: a review. ( Bruera, E; Sweeney, C, 2002) |
| "In our article ?Methadone switching for refractory cancer pain' (BMC palliative care, 2022) we explore the efficacy, safety and economics of methadone in treatment of patients with refractory cancer pain in China." | 4.31 | Reply to "A better interpretation of data regarding the opioid switching to methadone". ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2023) |
| "Methadone is commonly considered an alternative opioid treatment for refractory cancer pain." | 4.12 | Methadone switching for refractory cancer pain. ( Ding, H; Fang, L; Gong, L; He, C; Song, Y; Sun, J; Xin, W; Zhong, L; Zhou, Q, 2022) |
| "Methadone is a useful option in the treatment of cancer pain." | 4.12 | Methadone rotation for cancer pain: an observational study. ( Hum, A; Tan, C; Wong, JF; Yee, CM, 2022) |
| "The prevalence of poisoning from methadone and prescription opioids is increasing in pediatric populations." | 4.02 | A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children. ( Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N, 2021) |
| "To describe the titration phase of the treatment with low-dose first-line methadone and the use of methadone for breakthrough pain." | 4.02 | First-line methadone for cancer pain: titration time analysis. ( Armesto, A; Bertolino, M; Bruera, E; Bunge, S; Dran, G; Mammana, G; Orellana, F; Peirano, G; Vega, F, 2021) |
| "Although methadone has the potential to improve the management of cancer pain, it has some serious problems, such as respiratory depression and QT interval prolongation." | 4.02 | Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting. ( Matsuda, Y; Okayama, S, 2021) |
| "The effect of methadone on corrected QT interval (QTc) in patients with cancer pain is not well-known." | 3.91 | Evaluation of QTc Interval Prolongation Among Patients With Cancer Using Enteral Methadone. ( Hartman, A; Kale, SS; Lehman, A; Lovell, AG; Protus, BM; Saphire, ML, 2019) |
| "Methadone use as a second-line agent for severe cancer-related pain is increasing in the field of hospice and palliative care." | 3.85 | Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report. ( Hartwig, KN; Hoff, AM; Rosielle, DA, 2017) |
| "The use of methadone for cancer pain is limited by the need of expertise and close titration due to variable half-life." | 3.83 | Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit. ( Armesto, A; Bertolino, MS; Camerano, G; Dran, G; Mammana, GP; Pastrana, T; Peirano, GP; Ruggiero, R; Russo, J; Varela, G; Vega, GF; Vignaroli, E, 2016) |
| "Methadone offers many advantages for treating cancer pain." | 3.83 | Methadone as a Coanalgesic for Palliative Care Cancer Patients. ( Courtemanche, F; Dao, D; Gagné, F; Néron, A; Tremblay, L, 2016) |
| "Previous research has reported improved pain after adding methadone to another opioid, but did not quantify this benefit using a validated outcome measure." | 3.79 | Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. ( Bryson, J; Mak, E; Ridley, J; Wallace, E; Zimmermann, C, 2013) |
| "A retrospective, systematic chart review of levo-methadone conversions for the treatment of pain in inpatient palliative care was performed." | 3.78 | Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone. ( Gaertner, J; Klein, C; Nauck, F; Ostgathe, C; Sabatowski, R; Van Aaaken, A; Voltz, R, 2012) |
| "Switching to methadone from different opioids, using an initial fixed ratio followed by a flexible dosing, according to the clinical need, is highly effective and safe when performed in an acute pain relief and palliative care unit." | 3.78 | Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. ( Mercadante, S, 2012) |
| "A case of severe constipation is described in a 75-year- old cancer patient receiving methadone for pain." | 3.77 | Neostigmine for the treatment of gastrointestinal atony: a report of one case. ( Papa, P; Turconi, L, 2011) |
| "Methadone is an effective and inexpensive opioid for cancer pain treatment." | 3.76 | Methadone initiation and rotation in the outpatient setting for patients with cancer pain. ( Bruera, E; Calderon, B; de la Cruz, M; El Osta, B; Li, Z; Palmer, JL; Parsons, HA, 2010) |
| "We conducted a feasibility study of sublingual methadone for breakthrough cancer pain, to determine whether a larger, randomized trial was warranted, and to identify a study design that would be likely to succeed." | 3.76 | A formal feasibility study of sublingual methadone for breakthrough cancer pain. ( Biondo, PD; Brasher, PM; Eliasziw, M; Hagen, NA; Moulin, DE; Stiles, CR; Watanabe, SM, 2010) |
| "Racemic methadone is increasingly used to manage cancer pain." | 3.73 | Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. ( Auret, K; Boyd, F; Ilett, KF; Oh, TE; Page-Sharp, M; Roger Goucke, C, 2006) |
| "Methadone has been used as an alternative strong opioid to morphine in the management of cancer pain." | 3.72 | An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. ( Ma, HM; Ng, DK; Sham, MM; Tse, DM, 2003) |
| "An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain." | 3.71 | Morphine and alternative opioids in cancer pain: the EAPC recommendations. ( Casas, JR; Cherny, N; Conno, F; Hanks, GW; Hanna, M; Kalso, E; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Radbruch, L; Ripamonti, C; Sawe, J; Twycross, RG; Ventafridda, V, 2001) |
| "Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids." | 3.70 | Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. ( Bruera, ED; Hanson, J; Lawlor, PG; Turner, KS, 1998) |
| "Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain." | 3.70 | Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. ( Belzile, M; Bruera, E; De Conno, F; Groff, L; Hanson, J; Pereira, J; Ripamonti, C, 1998) |
| "To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone." | 3.70 | Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? ( Brunelli, C; De Conno, F; Groff, L; Polastri, D; Ripamonti, C; Stavrakis, A, 1998) |
| " In the past 2 years, oral methadone has been used extensively in our institution for treating children with persistent pain from cancer, burns, or trauma who were capable of oral intake and whose pain was not relieved by nonopioid medications." | 3.70 | Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases. ( Davidson, EM; Rosen, G; Shavelson, V; Shenkman, Z; Shir, Y, 1998) |
| "Hyperalgesia and allodynia in 4 cancer patients treated with morphine disappeared after discontinuing or substituting morphine with other opioid agonists." | 3.69 | Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. ( Jensen, NH; Jensen, TS; Sjøgren, P, 1994) |
| "The aims of this study were to describe the analgesia, side effects, and dosage and the causes of suspension of treatment in a large sample of advanced cancer patients with pain after treatment with oral methadone from 7 to 90 days." | 3.69 | Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. ( Brunelli, C; De Conno, F; Groff, L; Ripamonti, C; Ventafridda, V; Zecca, E, 1996) |
| "A sample if 41 patients with cancer-related pain in palliative setting were included." | 3.01 | A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain. ( Duarte, FCN; Ferraro, LHDC; Ferreira, A; Sakata, RK, 2021) |
| " Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3." | 2.82 | Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016) |
| "Forty-two cancer patients with pain and/or opioid side effects were assessed in this randomised trial." | 2.77 | Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. ( Dale, O; Kaasa, S; Moksnes, K; Paulsen, Ø; Rosland, JH; Spigset, O, 2012) |
| "Methadone was significantly less expensive, but required more changes, up and down, of the doses, suggesting that dose titration of this drug requires major clinical expertise." | 2.73 | Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. ( Aielli, F; Casuccio, A; Ferrera, P; Ficorella, C; Fulfaro, F; Gebbia, V; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L; Villari, P, 2008) |
| " A scoping review was performed to evaluate whether existing literature on methadone bioavailability in human subjects support the current recommendation that an equivalent enteral dose is twice the intravenous dose." | 2.72 | Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review. ( Craig, WY; Fraser, GL; Kemp, HD; Liu, J; McKelvy, DJ; Nichols, SD; Riker, RR; Smith, KE, 2021) |
| "Methadone was initiated 8-24 hours after fentanyl withdrawal, depending on the patient's previous opioid doses (from < 100 microg per hour to > 300 microg per hour)." | 2.71 | Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. ( Benítez-Rosario, MA; Feria, M; Martín-Ortega, JJ; Martínez-Castillo, LP; Salinas-Martín, A, 2004) |
| "Methadone is a drug of indisputable value in the treatment of cancer pain, and an unbalanced focus on the risks of inappropriate use rather than the benefits should not compromise the use of a relevant alternative to morphine in the management of cancer pain." | 2.69 | Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. ( Agnello, A; Barresi, L; Calderone, L; Casuccio, A; Mercadante, S; Serretta, R, 1998) |
| " After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)." | 2.68 | Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997) |
| " Dosing intervals, pain intensity assessments and toxicity were evaluated." | 2.66 | Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study. ( Enterline, J; Green, L; Grochow, L; Grossman, S; Sheidler, V, 1989) |
| "Thirty-two postoperative cancer patients received deltoid and gluteal injections of morphine, 8 and 16 mg, within a double-blind, twin crossover design." | 2.65 | Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine. ( Grabinski, PY; Houde, RW; Kaiko, RF; Rogers, AG, 1983) |
| "Methadone is an opioid that is only approved for replacement therapy in Austria." | 2.58 | Methadone as anticancer treatment: hype, hope, or hazard? : A series of case reports and a short review of the current literature and recommendations of the societies. ( Hackner, K; Kreye, G; Masel, EK; Nauck, F; Stich, B, 2018) |
| "Its administration against cancer pain is, however, tenable, albeit restricted to certain clinical situations." | 2.58 | Methadone against cancer: Lost in translation. ( Mikus, G; Theile, D, 2018) |
| "Methadone is a synthetic opioid with unique pharmacodynamic and pharmacokinetic properties." | 2.58 | Methadone for Pain Management in Children with Cancer. ( Anghelescu, DL; Habashy, C; Hall, EA; Springer, E, 2018) |
| "Refractory cancer pain that does not respond to standard opioid and/or co-analgesic therapy occurs in 10-20 % of patients." | 2.52 | Pharmacological options for the management of refractory cancer pain-what is the evidence? ( Afsharimani, B; Good, P; Hardy, J; Kindl, K, 2015) |
| "Up to 44% of patients with cancer-related pain require opioid rotation (OR) because of inadequate analgesia or side effects." | 2.52 | Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. ( McLean, S; Twomey, F, 2015) |
| "Methadone was used subcutaneously as an analgesic agent in 1 patient." | 2.47 | Review of cancer pain management in patients receiving maintenance methadone therapy. ( McLean, S; McQuillan, R; O'Gorman, A; Rowley, D; Ryan, K, 2011) |
| "Up to 80% of people with cancer experience pain at some time during their illness, and most will need opioid analgesics." | 2.44 | Opioids in people with cancer-related pain. ( Quigley, C, 2008) |
| " This article reviews the World Health Organization recommendations for analgesic therapy in this setting, as well as guidelines for opioid therapy in patients with renal failure or hepatic failure, assessment of pain, dosing strategies in both acute and chronic pain, management of opioid overdose, pain associated with dose-limiting side effects, and pain in the actively dying." | 2.44 | Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know. ( Davis, MP; Gamier, P; Lasheen, W, 2007) |
| "Ongoing assessment, multiple approaches, and excellent communication among all care management team members are critical." | 2.43 | Difficult cases in pain management: use of methadone in a multifactorial approach. ( Coyle, N; Coyne, P; Griffie, J, 2006) |
| "Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition." | 2.43 | Methadone for treatment of cancer pain. ( Bryson, J; Seccareccia, D; Tamber, A; Zimmermann, C, 2006) |
| " Regular pain assessments combined with appropriate analgesic administration at regular dosing intervals, adjunctive drug therapy for control of adverse effects and associated symptoms, and nonpharmacological interventions are recommended." | 2.42 | Cancer pain management in children. ( Mercadante, S, 2004) |
| "Methadone is a synthetic opioid, with mu and delta receptor activity, associated with the capacity to inhibit N-methyl-D-aspartate receptors." | 2.41 | Opioid switch to oral methadone in cancer pain. ( Body, JJ; Lossignol, DA; Mancini, I, 2000) |
| "Methadone is a potent synthetic opioid analgesic best known in Australia as maintenance therapy for narcotic addicts." | 2.41 | The rediscovery of methadone for cancer pain management. ( Ayonrinde, OT; Bridge, DT, 2000) |
| " When initiating treatment, controlled-release preparations of opioids are generally favoured, and are combined with immediate release morphine to prevent or treat 'breakthrough' pain and to enable the optimum opioid dosage to be calculated." | 2.41 | [Treatment of pain in cancer with systemically administered opioids]. ( de Wit, R; Enting, RH; Lieverse, PJ; Smitt, PA; van der Rijt, CC; Wilms, EB, 2001) |
| "Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain." | 2.40 | An update on the clinical use of methadone for cancer pain. ( Bruera, E; Ripamonti, C; Zecca, E, 1997) |
| "Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways." | 2.40 | [Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997) |
| " Issues to be explored include a potential role in treating patients who have poorly responsive pain syndromes, such as neuropathic pain, or who develop a rapid tolerance to other opioids; the possibility of extending dosing intervals to every 12 or 24 hours; and its possible use as a first-line opioid." | 2.40 | Role of methadone in the management of pain in cancer patients. ( Bruera, E; Neumann, CM, 1999) |
| "When pain is relieved inadequately by opioid analgesics given in a dose that causes intolerable side effects despite routine measures to control them, treatment with the same opioid by an alternative route or with an alternative opioid administered by the same route should be considered." | 2.40 | Opioid rotation for cancer pain: rationale and clinical aspects. ( Mercadante, S, 1999) |
| "Methadone is a synthetic opiate receptor agonist that has been available for more than 40 years." | 2.38 | Methadone in the management of cancer pain: a review. ( Bruera, E; Fainsinger, R; Schoeller, T, 1993) |
| "Trigeminal neuralgia (TN) secondary to malignancy leads to significant distress and subsequently impacts a patient's quality of life." | 1.91 | Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report. ( Akel, R; Bromberg, H; Craig, D; Guastella, A; Haas, M, 2023) |
| "Methadone doses were changed according to the clinical needs to obtain the most favorable balance between analgesia and adverse effects." | 1.72 | Methadone as First-line Opioid for the Management of Cancer Pain. ( Adile, C; Bonanno, G; Casuccio, A; Ferrera, P; Mercadante, S; Pallotti, MC; Ricci, M, 2022) |
| "Opioid misuse and opioid use disorder (OUD) are important comorbidities in people with advanced cancer and cancer-related pain, but there is a lack of consensus on treatment." | 1.72 | Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder. ( Arnold, R; Bulls, H; Dao, E; Fitzgerald Jones, K; Kapo, J; Khodyakov, D; Liebschutz, J; Meier, D; Merlin, J; Paice, J; Ritchie, C, 2022) |
| " There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians." | 1.72 | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life. ( Albury, CL; George, R; Good, P; Griffiths, LR; Hardy, J; Haupt, LM; Haywood, A; Ozberk, D; Sutherland, HG; Yu, C; Zunk, M, 2022) |
| "MR for CIBP may result in reduction in pain intensity, when other opioids are ineffective or intolerable, with patients requiring reduced overall dosing of their long-acting opioid and frequency of breakthrough opioid use." | 1.62 | The role of methadone in cancer-induced bone pain: a retrospective cohort study. ( Al-Rubaie, Z; Key, S; Kwok, J; Michael, N; Sulistio, M; Wojnar, R, 2021) |
| " An individualized approach to dosage and route should be considered based on specific clinical circumstances." | 1.62 | Methadone for Cancer Pain in Pediatric End-of-Life Care. ( Anghelescu, DL; Habashy, C; Hall, EA; Sauer, HE, 2021) |
| "All study participants reported cancer pain with neuropathic components; most had mixed pain syndromes comprising nociceptive and neuropathic components." | 1.62 | Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study. ( Abdullaziz, S; Curry, ZA; Dang, MC; Del Fabbro, EG; Sima, AP, 2021) |
| "Opioids are the first-line treatment for cancer pain." | 1.62 | Antinociceptive synergism upon the joint use of methadone and Phα1β in a model of cancer-related pain in C57BL/6J mice. ( Aoki, CT; Castro Junior, CJ; Delgado, MA; Ferreira, J; Ferreira, LA; Gomez, MV; Mendes, MP; Moura, RA; Rezende, MJ; Santos, DC, 2021) |
| "Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach." | 1.51 | Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. ( Anghelescu, DL; Tesney, JM, 2019) |
| "Methadone can cause a prolonged QTc interval that can lead to ventricular arrhythmias." | 1.46 | The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain. ( Bruera, E; Liu, D; Madden, K; Park, M, 2017) |
| "Methadone has been associated with lower overall survival (OS) in patients with chronic pain." | 1.46 | Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids. ( Bruera, E; de la Cruz, M; Liu, D; Reddy, A; Schuler, US; Wu, J; Yennurajalingam, S, 2017) |
| "IV-PCA provided timely, safe and useful analgesia for patients with severe breakthrough pain and may be useful to help titration of opioids, weaning to oral analgesia and to decide for interventional procedures." | 1.40 | Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study. ( Ashmawi, HA; Cascudo, GM; de Santana Neto, J; Guimaraes, GM; Neto, JO; Sousa, AM, 2014) |
| "Methadone was discontinued in one patient on D7 because it was deemed ineffective and for 8 patients, who were unable to take oral drugs, it was discontinued after D14." | 1.39 | Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. ( Bruera, E; Ciais, JF; Filbet, M; Ledoux, M; Rhondali, W; Tremellat, F, 2013) |
| "This study explored cancer incidence rates in a large cohort of Israeli (Jewish and Arab) opioid-dependent individuals receiving methadone maintenance treatment (MMT), and how the incidences vary by ethnicity and sex." | 1.37 | Methadone maintenance and cancer risk: an Israeli case registry study. ( Barchana, M; Grinshpoon, A; Lipshitz, I; Ponizovsky, AM; Rosca, P; Weizman, A, 2011) |
| "This paper reports two cases of myoclonus with high-dose parenteral methadone in patients with cancer under hospice care." | 1.35 | Myoclonus associated with high-dose parenteral methadone. ( Ito, S; Liao, S, 2008) |
| "Pain is an important and often under-treated symptom of life-threatening illness." | 1.35 | [Analgesics and palliative care]. ( Mathieu, N; Tuna, T, 2008) |
| "Methadone (ME) is a highly effective opioid agonist used for difficult pain syndromes." | 1.35 | Switching from methadone to a different opioid: what is the equianalgesic dose ratio? ( Bruera, E; Hanohano, J; Kaur, G; Munsell, M; Palla, S; Pei, BL; Walker, PW; Zhang, K, 2008) |
| "7), which approximates the bioavailability of the drug administered orally." | 1.35 | Conversion from parenteral to oral methadone. ( Gómez-Batiste, X; González-Barboteo, J; Porta-Sales, J; Sánchez, D; Tuca, A, 2008) |
| "We analyzed 54 cancer patients undergoing opioid rotation to clarify those factors that influenced the morphine/methadone dose ratio (MMEDR) at Day 10 after the switch." | 1.35 | Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. ( Aguirre-Jaime, A; Benítez-Rosario, MA; Feria, M; Pérez-Méndez, L; Salinas-Martín, A, 2009) |
| "Cancer pain is common, occurring in up to 60% of patients and opioid conversion may be required for effective pain management." | 1.35 | Inconsistencies in opioid equianalgesic ratios: clinical and research implications. ( Kutner, JS; Linnebur, SA; O'Bryant, CL; Yamashita, TE, 2008) |
| "Methadone was used for a total of 925 patient-days." | 1.35 | Methadone analgesia for children with advanced cancer. ( Davies, D; DeVlaming, D; Haines, C, 2008) |
| "Fentanyl patches were removed and the first of three daily doses of methadone was started concurrently." | 1.34 | Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ( Casuccio, A; Ferrera, P; Gambaro, V; Mercadante, S; Villari, P, 2007) |
| "Methadone is a synthetic opioid agonist and N-methyl-D-aspartate (NMDA) receptor antagonist that is being increasingly used in pain management, particularly for pain that is resistant to conventional opioids." | 1.33 | Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? ( Booth, CM; Cottrell, W; Seccareccia, D; Zimmermann, C, 2005) |
| "Methadone daily dosage was also analyzed during this study." | 1.32 | Methadone and the hospice patient: prescribing trends in the home-care setting. ( Alt, CJ; Gallagher, R; Knowlton, CH; McMath, JA; Weschules, DJ, 2003) |
| " For this reason, methadone is often viewed as a second line opioid, after other opioids with a more predictable dose-response have been tried." | 1.31 | Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. ( Cheville, AL; Gonzales, GR; Kornick, C; Manfredi, PL; Payne, R, 2001) |
| " Various strategies have been proposed to estimate safe and effective starting doses of methadone when rotating from morphine and hydromorphone; however, there are no guidelines for estimating safe and effective starting doses of methadone when rotating from fentanyl." | 1.31 | Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. ( Fischberg, DJ; Khojainova, N; Kornick, C; Manfredi, P; Payne, R; Primavera, LH; Santiago-Palma, J, 2001) |
| "To assess the effect of opioid substitution (substituting one member of the opioid class for another) on the incidence and severity of adverse effects in palliative care patients who experience unacceptable, refractory adverse effects when taking an opioid drug." | 1.30 | Opioid substitution to reduce adverse effects in cancer pain management. ( Ashby, MA; Jackson, KA; Martin, P, 1999) |
| "Methadone dose was significantly higher in patients who had lower preswitching doses of morphine and vice versa." | 1.30 | Rapid switching from morphine to methadone in cancer patients with poor response to morphine. ( Calderone, L; Casuccio, A; Mercadante, S, 1999) |
| "Methadone can be an effective drug for cancer pain but it can also be difficult to use safely." | 1.30 | Methadone: outpatient titration and monitoring strategies in cancer patients. ( Hagen, NA; Wasylenko, E, 1999) |
| "Dipipanone elixir was formulated 10 mg/5 ml, in single strength chloroform water." | 1.29 | Experience with dipipanone elixir in the management of cancer related pain--case study. ( Ahmedzai, S; Faull, C; McKechnie, E; Riley, J, 1994) |
| "Methadone is a synthetic opioid with excellent oral bioavailability, variable, but long duration of action and extremely low cost." | 1.29 | Respiratory depression in a patient receiving oral methadone for cancer pain. ( Bruera, E; Hunt, G, 1995) |
| "Methadone is a potent opioid analgesic that demonstrates incomplete cross-tolerance with other mu-opioid receptor agonist analgesics." | 1.29 | Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. ( Crews, JC; Denson, DD; Sweeney, NJ, 1993) |
| "To study the incidence of AIDS-defining and non-AIDS-defining malignancies in injecting drug users with and without HIV infection in a methadone maintenance treatment program (MMTP)." | 1.28 | Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985-1991. ( Budner, NS; Gachupin-Garcia, A; Selwyn, PA, 1992) |
| "Seventy cancer patients suffering from visceral or somatic pain received continuous epidural methadone (EM) analgesia." | 1.28 | Continuous epidural methadone treatment for cancer pain. ( Kaufman, B; Magora, F; Shapira, SS; Shenkman, Z; Shir, Y, 1991) |
| "Morphine was used in 36 CIs, methadone in four, hydromorphone in four, oxymorphone in one, and levorphanol in one." | 1.27 | I.v. infusion of opioids for cancer pain: clinical review and guidelines for use. ( Foley, KM; Inturrisi, CE; Moulin, DE; Portenoy, RK; Rogers, A, 1986) |
| "Neither the type nor incidence of neoplasia was drug related but a few nonneoplastic lesions may have been." | 1.27 | In vivo carcinogenesis assay of DL-methadone.HCl in rodents. ( Fleischman, RW; Rosenkrantz, H, 1988) |
| "The long half-life and wide inter-patient variability in clearance of methadone make this drug difficult to use optimally." | 1.27 | Estimation of methadone clearance: application in the management of cancer pain. ( Cherry, DA; Cousins, MJ; Gourlay, GK; Plummer, JL, 1988) |
| " As expected, the dosage intervals increased gradually over the first few days of treatment, the daily dose decreasing from 30-80 mg on the first day to 10-40 mg at the end of the week." | 1.26 | Patient-controlled dose regimen of methadone for chronic cancer pain. ( Anggård, E; Ginman, C; Hansen, J; Hartvig, P; Jakobsson, PA; Nilsson, MI; Rane, A; Säwe, J, 1981) |
| " Rapid and continuous pain relief without serious side-effects was achieved by "ad libitum" dosage in the first 3-5 days." | 1.26 | Clinical evaluation of oral methadone in treatment of cancer pain. ( Anggård, E; Ginman, C; Hansen, J; Hartvig, P; Jakobsson, PA; Nilsson, MI; Rane, A; Säwe, J, 1982) |
| "Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively." | 1.26 | Important clinical pharmacologic considerations in the use of methadone in cancer patients. ( Ettinger, DS; Trump, DL; Vitale, PJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (17.49) | 18.7374 |
| 1990's | 41 (18.39) | 18.2507 |
| 2000's | 60 (26.91) | 29.6817 |
| 2010's | 53 (23.77) | 24.3611 |
| 2020's | 30 (13.45) | 2.80 |
| Authors | Studies |
|---|---|
| Irwin, MN | 1 |
| Ellingrod, VL | 1 |
| Smith, MA | 1 |
| Takemura, M | 1 |
| Niki, K | 1 |
| Okamoto, Y | 1 |
| Matsuda, Y | 2 |
| Omae, T | 1 |
| Takagi, T | 1 |
| Ueda, M | 1 |
| Treillet, E | 1 |
| Giet, O | 1 |
| Picard, S | 1 |
| Laurent, S | 1 |
| Seresse, L | 1 |
| Ozberk, D | 2 |
| Haywood, A | 4 |
| Sutherland, HG | 2 |
| Yu, C | 2 |
| Albury, CL | 2 |
| Zunk, M | 2 |
| George, R | 3 |
| Good, P | 5 |
| Griffiths, LR | 2 |
| Hardy, J | 5 |
| Haupt, LM | 2 |
| Mercadante, S | 27 |
| Adile, C | 5 |
| Ferrera, P | 9 |
| Pallotti, MC | 1 |
| Ricci, M | 1 |
| Bonanno, G | 1 |
| Casuccio, A | 14 |
| Fitzgerald Jones, K | 1 |
| Khodyakov, D | 1 |
| Arnold, R | 1 |
| Bulls, H | 1 |
| Dao, E | 1 |
| Kapo, J | 1 |
| Meier, D | 2 |
| Paice, J | 1 |
| Liebschutz, J | 1 |
| Ritchie, C | 1 |
| Merlin, J | 2 |
| Ding, H | 2 |
| Song, Y | 3 |
| Xin, W | 2 |
| Sun, J | 4 |
| Zhong, L | 2 |
| Zhou, Q | 3 |
| He, C | 4 |
| Gong, L | 2 |
| Fang, L | 2 |
| Grassi, Y | 1 |
| Cascio, AL | 2 |
| Bromberg, H | 1 |
| Guastella, A | 1 |
| Haas, M | 1 |
| Akel, R | 1 |
| Craig, D | 1 |
| Dräger, DL | 1 |
| Jones, KF | 1 |
| Joudrey, P | 1 |
| Meghani, S | 1 |
| Fürst, P | 1 |
| Lundström, S | 1 |
| Klepstad, P | 2 |
| Strang, P | 1 |
| David, F | 1 |
| Villari, P | 7 |
| Spedale, VM | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 5 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 7 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 3 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 2 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Tan, C | 1 |
| Wong, JF | 1 |
| Yee, CM | 1 |
| Hum, A | 2 |
| Sulistio, M | 2 |
| Wojnar, R | 1 |
| Key, S | 1 |
| Kwok, J | 1 |
| Al-Rubaie, Z | 1 |
| Michael, N | 1 |
| Hall, EA | 2 |
| Sauer, HE | 1 |
| Habashy, C | 2 |
| Anghelescu, DL | 3 |
| Gholami, N | 1 |
| Farnaghi, F | 1 |
| Saberi, M | 1 |
| Zamani, N | 1 |
| McDonald, R | 1 |
| Hassanian-Moghaddam, H | 1 |
| Curry, ZA | 1 |
| Dang, MC | 1 |
| Sima, AP | 1 |
| Abdullaziz, S | 1 |
| Del Fabbro, EG | 1 |
| Smith, KE | 1 |
| Riker, RR | 1 |
| Craig, WY | 1 |
| McKelvy, DJ | 1 |
| Kemp, HD | 1 |
| Nichols, SD | 1 |
| Fraser, GL | 1 |
| Mammana, G | 1 |
| Bertolino, M | 2 |
| Bruera, E | 24 |
| Orellana, F | 1 |
| Vega, F | 1 |
| Peirano, G | 1 |
| Bunge, S | 1 |
| Armesto, A | 2 |
| Dran, G | 2 |
| Ferreira, LA | 1 |
| Aoki, CT | 1 |
| Santos, DC | 1 |
| Rezende, MJ | 1 |
| Mendes, MP | 1 |
| Moura, RA | 1 |
| Delgado, MA | 1 |
| Ferreira, J | 1 |
| Gomez, MV | 1 |
| Castro Junior, CJ | 1 |
| Duarte, FCN | 1 |
| Ferraro, LHDC | 1 |
| Ferreira, A | 1 |
| Sakata, RK | 1 |
| Okayama, S | 1 |
| Madden, K | 1 |
| Park, M | 1 |
| Liu, D | 2 |
| Hoff, AM | 1 |
| Hartwig, KN | 1 |
| Rosielle, DA | 1 |
| van den Beuken-van Everdingen, MHJ | 1 |
| van Kuijk, SMJ | 1 |
| Joosten, EA | 1 |
| Hennig, S | 1 |
| Khan, S | 2 |
| Norris, R | 1 |
| Aiyer, R | 1 |
| Gulati, A | 1 |
| Gungor, S | 1 |
| Bhatia, A | 1 |
| Mehta, N | 1 |
| Kreye, G | 1 |
| Masel, EK | 1 |
| Hackner, K | 1 |
| Stich, B | 1 |
| Nauck, F | 2 |
| Theile, D | 1 |
| Mikus, G | 1 |
| McPherson, ML | 1 |
| Costantino, RC | 1 |
| McPherson, AL | 1 |
| Springer, E | 1 |
| Picco Brunetto, AG | 1 |
| Lovell, AG | 1 |
| Protus, BM | 1 |
| Saphire, ML | 1 |
| Kale, SS | 1 |
| Lehman, A | 1 |
| Hartman, A | 1 |
| Tesney, JM | 1 |
| Piccininni, JA | 1 |
| Killinger, JS | 1 |
| Hammad, HT | 1 |
| Gerber, LM | 1 |
| Dayton, JD | 1 |
| Gregg, JL | 1 |
| Prestia, G | 1 |
| Hadley, G | 1 |
| Derry, S | 2 |
| Moore, RA | 1 |
| Wiffen, PJ | 2 |
| Rhondali, W | 1 |
| Tremellat, F | 1 |
| Ledoux, M | 1 |
| Ciais, JF | 1 |
| Filbet, M | 1 |
| Sousa, AM | 1 |
| de Santana Neto, J | 1 |
| Guimaraes, GM | 1 |
| Cascudo, GM | 1 |
| Neto, JO | 1 |
| Ashmawi, HA | 1 |
| Didwaniya, N | 1 |
| Reddy, A | 2 |
| Gottumukkala, RS | 1 |
| Afsharimani, B | 2 |
| Movva, R | 1 |
| Rasmussen, VF | 1 |
| Lundberg, V | 1 |
| Jespersen, TW | 1 |
| Hasle, H | 1 |
| Kindl, K | 1 |
| McLean, S | 2 |
| Twomey, F | 1 |
| Peirano, GP | 1 |
| Mammana, GP | 1 |
| Bertolino, MS | 1 |
| Pastrana, T | 1 |
| Vega, GF | 1 |
| Russo, J | 1 |
| Varela, G | 1 |
| Vignaroli, E | 1 |
| Ruggiero, R | 1 |
| Camerano, G | 1 |
| Porta-Sales, J | 2 |
| Garzón-Rodríguez, C | 1 |
| Villavicencio-Chávez, C | 1 |
| Llorens-Torromé, S | 1 |
| González-Barboteo, J | 3 |
| Courtemanche, F | 1 |
| Dao, D | 1 |
| Gagné, F | 1 |
| Tremblay, L | 1 |
| Néron, A | 1 |
| Ruan, X | 1 |
| Luo, JJ | 1 |
| Kaye, AD | 1 |
| Schuler, US | 1 |
| de la Cruz, M | 3 |
| Yennurajalingam, S | 2 |
| Hofbauer, H | 1 |
| Schenk, M | 1 |
| Kieselbach, K | 1 |
| Wirz, S | 1 |
| Nicholson, AB | 3 |
| Watson, GR | 1 |
| Juba, KM | 1 |
| Khadem, TM | 1 |
| Hutchinson, DJ | 1 |
| Brown, JE | 1 |
| Bond, BS | 1 |
| Prommer, EE | 2 |
| Ito, S | 1 |
| Liao, S | 1 |
| Mathieu, N | 1 |
| Tuna, T | 1 |
| Walker, PW | 1 |
| Palla, S | 1 |
| Pei, BL | 1 |
| Kaur, G | 1 |
| Zhang, K | 1 |
| Hanohano, J | 1 |
| Munsell, M | 1 |
| Sánchez, D | 1 |
| Tuca, A | 1 |
| Gómez-Batiste, X | 2 |
| Leppert, W | 2 |
| Benítez-Rosario, MA | 2 |
| Salinas-Martín, A | 2 |
| Aguirre-Jaime, A | 1 |
| Pérez-Méndez, L | 1 |
| Feria, M | 2 |
| Cubero, DI | 1 |
| del Giglio, A | 1 |
| Quigley, C | 1 |
| Fine, PG | 1 |
| Reddy, S | 2 |
| Hui, D | 1 |
| El Osta, B | 2 |
| Walker, P | 1 |
| Palmer, JL | 3 |
| Parsons, HA | 1 |
| Calderon, B | 1 |
| Portenoy, RK | 3 |
| Heppe, DB | 1 |
| Haigney, MC | 1 |
| Krantz, MJ | 1 |
| Hagen, NA | 4 |
| Moulin, DE | 2 |
| Brasher, PM | 1 |
| Biondo, PD | 1 |
| Eliasziw, M | 1 |
| Watanabe, SM | 1 |
| Stiles, CR | 1 |
| Trelis-Navarro, J | 1 |
| Tuca-Rodríguez, A | 1 |
| Rowley, D | 1 |
| O'Gorman, A | 1 |
| Ryan, K | 1 |
| McQuillan, R | 1 |
| Arcuri, E | 1 |
| Papa, P | 1 |
| Turconi, L | 1 |
| Grinshpoon, A | 1 |
| Barchana, M | 1 |
| Lipshitz, I | 1 |
| Rosca, P | 1 |
| Weizman, A | 1 |
| Ponizovsky, AM | 1 |
| Cherny, N | 2 |
| Moksnes, K | 2 |
| Dale, O | 2 |
| Rosland, JH | 2 |
| Paulsen, O | 1 |
| Kaasa, S | 2 |
| O'Bryant, CL | 1 |
| Linnebur, SA | 1 |
| Yamashita, TE | 1 |
| Kutner, JS | 1 |
| Ostgathe, C | 1 |
| Voltz, R | 1 |
| Van Aaaken, A | 1 |
| Klein, C | 1 |
| Sabatowski, R | 2 |
| Gaertner, J | 1 |
| Paulsen, Ø | 1 |
| Spigset, O | 1 |
| Lauretti, GR | 1 |
| Rizzo, CC | 1 |
| Mattos, AL | 1 |
| Rodrigues, SW | 1 |
| Jackson, K | 1 |
| Wallace, E | 1 |
| Ridley, J | 1 |
| Bryson, J | 2 |
| Mak, E | 1 |
| Zimmermann, C | 3 |
| Ripamonti, C | 11 |
| Bianchi, M | 5 |
| Miles, J | 1 |
| Breitfeld, C | 1 |
| Eikermann, M | 1 |
| Kienbaum, P | 1 |
| Peters, J | 1 |
| Fulfaro, F | 3 |
| Gebbia, V | 3 |
| Tse, DM | 1 |
| Sham, MM | 1 |
| Ng, DK | 1 |
| Ma, HM | 1 |
| Weschules, DJ | 1 |
| McMath, JA | 1 |
| Gallagher, R | 1 |
| Alt, CJ | 1 |
| Knowlton, CH | 1 |
| DUNDEE, JW | 1 |
| Bosnjak, S | 1 |
| Rico, MA | 1 |
| Moyano, J | 1 |
| Sweeney, C | 2 |
| Strasser, F | 1 |
| Willey, J | 1 |
| Mathias, C | 1 |
| Spruyt, O | 1 |
| Fisch, MJ | 1 |
| Wootton, M | 1 |
| Fisch, M | 1 |
| Martínez-Castillo, LP | 1 |
| Martín-Ortega, JJ | 1 |
| Fisher, K | 2 |
| Stiles, C | 2 |
| Braiteh, F | 1 |
| Centeno, C | 1 |
| Vara, F | 1 |
| Seccareccia, D | 2 |
| Booth, CM | 1 |
| Cottrell, W | 1 |
| Griffie, J | 1 |
| Coyne, P | 1 |
| Coyle, N | 1 |
| Auret, K | 1 |
| Roger Goucke, C | 1 |
| Ilett, KF | 1 |
| Page-Sharp, M | 1 |
| Boyd, F | 1 |
| Oh, TE | 1 |
| Moryl, N | 2 |
| Kogan, M | 1 |
| Comfort, C | 1 |
| Obbens, E | 1 |
| Tamber, A | 1 |
| Gambaro, V | 1 |
| Davis, MP | 2 |
| Lasheen, W | 1 |
| Gamier, P | 1 |
| Fainsinger, RL | 3 |
| Bielech, M | 1 |
| Porzio, G | 1 |
| Aielli, F | 1 |
| Verna, L | 1 |
| Ficorella, C | 1 |
| Riina, S | 1 |
| Mangione, S | 1 |
| Davies, D | 1 |
| DeVlaming, D | 1 |
| Haines, C | 1 |
| Reich, SD | 1 |
| Säwe, J | 3 |
| Hansen, J | 2 |
| Ginman, C | 2 |
| Hartvig, P | 2 |
| Jakobsson, PA | 2 |
| Nilsson, MI | 2 |
| Rane, A | 2 |
| Anggård, E | 2 |
| Madsen, OG | 1 |
| Christoffersen, I | 1 |
| Philbert, A | 1 |
| Paalzow, L | 3 |
| Andersson, B | 2 |
| Lööf, G | 2 |
| Kullman, S | 1 |
| Kepes, ER | 1 |
| Raj, S | 1 |
| Thomas, P | 1 |
| Vemulapalli, K | 1 |
| Ferrer-Brechner, T | 1 |
| Ganz, P | 1 |
| Powers, DA | 1 |
| Hamilton, CW | 1 |
| Roberts, KB | 1 |
| Hanks, GW | 2 |
| Twycross, R | 1 |
| Grabinski, PY | 2 |
| Kaiko, RF | 2 |
| Rogers, AG | 1 |
| Houde, RW | 2 |
| Jaspersen, HP | 1 |
| Pierce, J | 1 |
| Ya Deau, RE | 1 |
| Maxwell, MB | 2 |
| Martinson, IM | 1 |
| Nixon, S | 1 |
| Geis, D | 1 |
| YaDeau, R | 1 |
| Nesbit, M | 1 |
| Kersey, J | 1 |
| Breivik, H | 2 |
| Rennemo, F | 1 |
| Nilsson, L | 1 |
| Stenberg, P | 1 |
| Portnow, JM | 1 |
| Corbett, RJ | 1 |
| Abramson, FP | 1 |
| Faull, C | 1 |
| McKechnie, E | 1 |
| Riley, J | 1 |
| Ahmedzai, S | 1 |
| Leng, G | 1 |
| Finnegan, MJ | 1 |
| Hunt, G | 1 |
| Crews, JC | 1 |
| Sweeney, NJ | 1 |
| Denson, DD | 1 |
| Sjøgren, P | 1 |
| Jensen, NH | 1 |
| Jensen, TS | 1 |
| Samuelsson, H | 1 |
| Ekman, R | 1 |
| Hedner, T | 1 |
| Fainsinger, R | 2 |
| Schoeller, T | 1 |
| Watanabe, S | 3 |
| Spachynski, K | 1 |
| Suarez-Almazor, M | 1 |
| Inturrisi, C | 1 |
| O'Rourke, MA | 1 |
| Shalabi, A | 1 |
| Webb, S | 1 |
| Belzile, M | 3 |
| Kuehn, N | 2 |
| Hanson, J | 4 |
| Pereira, J | 2 |
| De Conno, F | 5 |
| Groff, L | 5 |
| Brunelli, C | 2 |
| Zecca, E | 3 |
| Ventafridda, V | 4 |
| Sapio, M | 2 |
| Serretta, R | 3 |
| Caligara, M | 2 |
| Zacny, JP | 1 |
| Dardanoni, G | 1 |
| Barresi, L | 3 |
| Polastri, D | 2 |
| Fitzgibbon, DR | 1 |
| Ready, BL | 1 |
| Lawlor, PG | 1 |
| Turner, KS | 1 |
| Bruera, ED | 1 |
| Makin, MK | 1 |
| Ellershaw, JE | 1 |
| River, Y | 1 |
| Belgrade, M | 1 |
| Foley, KM | 4 |
| Stavrakis, A | 1 |
| Agnello, A | 2 |
| Calderone, L | 2 |
| Shir, Y | 3 |
| Shenkman, Z | 2 |
| Shavelson, V | 1 |
| Davidson, EM | 1 |
| Rosen, G | 2 |
| Ashby, MA | 1 |
| Martin, P | 1 |
| Jackson, KA | 1 |
| Clavenna, A | 1 |
| Scholes, CF | 1 |
| Gonty, N | 1 |
| Trotman, IF | 1 |
| Neumann, CM | 1 |
| Wasylenko, E | 1 |
| Berland, D | 1 |
| Oneschuk, D | 1 |
| Mancini, I | 1 |
| Lossignol, DA | 1 |
| Body, JJ | 1 |
| Shvelzon, V | 1 |
| McCaffery, M | 1 |
| Pasero, C | 1 |
| Ayonrinde, OT | 1 |
| Bridge, DT | 1 |
| Manfredi, PL | 2 |
| Gonzales, GR | 1 |
| Cheville, AL | 1 |
| Kornick, C | 3 |
| Payne, R | 3 |
| Conno, F | 1 |
| Hanna, M | 1 |
| Kalso, E | 1 |
| McQuay, HJ | 1 |
| Meynadier, J | 1 |
| Poulain, P | 1 |
| Radbruch, L | 2 |
| Casas, JR | 1 |
| Twycross, RG | 1 |
| Walsh, D | 1 |
| Boffi, R | 1 |
| Enting, RH | 1 |
| van der Rijt, CC | 1 |
| Wilms, EB | 1 |
| Lieverse, PJ | 1 |
| de Wit, R | 1 |
| Smitt, PA | 1 |
| Clark, KJ | 1 |
| Turner, K | 1 |
| Dickerson, ED | 2 |
| Santiago-Palma, J | 2 |
| Khojainova, N | 1 |
| Fischberg, DJ | 1 |
| Primavera, LH | 1 |
| Manfredi, P | 1 |
| Kasper, SM | 1 |
| Derby, S | 1 |
| Fischberg, D | 1 |
| Lamerton, RC | 1 |
| Valentine, AS | 1 |
| Steckel, S | 1 |
| Weintraub, M | 1 |
| Ettinger, DS | 1 |
| Vitale, PJ | 1 |
| Trump, DL | 1 |
| Watterson, O | 1 |
| Simpson, DD | 1 |
| Sells, SB | 1 |
| Gachupin-Garcia, A | 1 |
| Selwyn, PA | 1 |
| Budner, NS | 1 |
| Shapira, SS | 1 |
| Kaufman, B | 1 |
| Magora, F | 1 |
| Lang, AH | 1 |
| Abbrederis, K | 1 |
| Dzien, A | 1 |
| Drexel, H | 1 |
| Moore, M | 1 |
| Thibault, R | 1 |
| Spoldi, E | 1 |
| Inturrisi, CE | 4 |
| Max, MB | 2 |
| Colburn, WA | 1 |
| Li, CH | 1 |
| Rogers, A | 1 |
| Lo, SL | 1 |
| Coleman, RR | 1 |
| Grochow, L | 1 |
| Sheidler, V | 1 |
| Grossman, S | 1 |
| Green, L | 1 |
| Enterline, J | 1 |
| Rosenkrantz, H | 2 |
| Fleischman, RW | 2 |
| Paredes, H | 1 |
| Hernández, A | 1 |
| San Martín, S | 1 |
| Arraztoa, J | 1 |
| Plummer, JL | 1 |
| Gourlay, GK | 2 |
| Cherry, DA | 2 |
| Cousins, MJ | 2 |
| Sbanotto, A | 1 |
| Richlin, DM | 1 |
| Jamron, LM | 1 |
| Novick, NL | 1 |
| Mullan, S | 1 |
| Verebely, K | 1 |
| Sadove, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analgesic Effect Evaluation of Methadone Associated With Morphine for Cancer Pain: Prospective Randomized Study[NCT03324815] | 40 participants (Anticipated) | Interventional | 2017-03-02 | Recruiting | |||
| Prospective Randomized Simple Blinded Study Comparing Two Conversion Ratios From Parenteral to Oral Methadone in Patients With Cancer Pain.[NCT01836328] | Phase 3 | 44 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Randomized Double-blind Controlled Study to Assess the Efficacy of Intravenous Acetaminophen Associated With Strong Opioids in the Management of Acute Pain in Adult Cancer Patients[NCT04779567] | Phase 4 | 112 participants (Actual) | Interventional | 2019-06-10 | Completed | ||
| Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study[NCT00184496] | Phase 3 | 42 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects[NCT00504413] | Phase 1 | 20 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study[NCT00525967] | Phase 2/Phase 3 | 50 participants (Anticipated) | Interventional | 2006-02-28 | Recruiting | ||
| A Randomized Blinded Prospective Trial Comparing Single Intraoperative Dose of Methadone Versus Placebo in Pediatric Patients Undergoing Spine Surgery.[NCT02206685] | Phase 4 | 74 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management[NCT02335398] | Phase 4 | 34 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction[NCT01205256] | Phase 3 | 11 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were given access to Patient-Controlled Intravenous Opioid Administration (PCA) to manage their post-operative pain. The doses of morphine were calculated at at PACU, 24 hours, 48 hours and 72 hours respectively. (NCT02206685)
Timeframe: Admission to PACU to 72 hours post-operative
| Intervention | mg/kg (Median) | |||
|---|---|---|---|---|
| PACU | 24 Hours | 48 Hours | 72 Hours | |
| Control Group | 0.47 | 0.55 | 0.55 | 0.04 |
| Treatment Group | 0.41 | 0.58 | 0.58 | 0.10 |
The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The data reported here represents the mean difference in FLACC score by treatment group at PACU, 24 hours, 48 hours and 72 hours, respectively. (NCT02206685)
Timeframe: Admission to PACU to 72 hours post-operative
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PACU | 24 Hours | 48 Hours | 72 Hours | |
| Control Group | 0.65 | 0.42 | 0.36 | 0.29 |
| Treatment Group | 0.53 | 0.14 | 0.24 | 0.16 |
44 reviews available for methadone and Neoplasms
| Article | Year |
|---|---|
Methadone Switching for Cancer Pain: A New Classification of Initiation Protocols, Based on a Critical Literature Review.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms; Pain; Randomized Controlled | 2021 |
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Chronic Pain; Humans; Methadone; Neoplasms; Pain, Posto | 2023 |
Opioid-induced Neurotoxicity in Patients with Cancer Pain.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Palliative Care | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review.
Topics: Administration, Intravenous; Analgesics, Opioid; Biological Availability; Humans; Methadone; Neoplas | 2021 |
Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Sublingual; Analgesics, Opioid; B | 2018 |
Methadone as anticancer treatment: hype, hope, or hazard? : A series of case reports and a short review of the current literature and recommendations of the societies.
Topics: Analgesics, Opioid; Austria; Female; Germany; Humans; Methadone; Middle Aged; Morphine; Neoplasms; P | 2018 |
Methadone against cancer: Lost in translation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Methadone; Neoplasms | 2018 |
Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer.
Topics: Half-Life; Humans; Inappropriate Prescribing; Methadone; Neoplasms; Pain | 2018 |
Methadone for Pain Management in Children with Cancer.
Topics: Analgesics, Opioid; Cancer Pain; Child; Humans; Methadone; Neoplasms; Pain Management; Pain Measurem | 2018 |
Transdermal fentanyl for cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pai | 2013 |
Therapeutic challenges in cancer pain management: a systematic review of methadone.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Pain Management | 2014 |
Pharmacological options for the management of refractory cancer pain-what is the evidence?
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; B | 2015 |
Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Pain Management | 2015 |
Methadone for cancer pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Humans; Methadone; Middle Aged; Morphine; Neopla | 2017 |
Equianalgesia: applying evidence-based practice guidelines.
Topics: Analgesia; Analgesics, Opioid; Codeine; Drug Monitoring; Evidence-Based Medicine; Humans; Hydromorph | 2008 |
Opioids in people with cancer-related pain.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Codeine; Fentanyl; Humans; Methadone; Neoplasm | 2008 |
Clinical approaches to special issues related to opioid therapy.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Nurse's Role; Nursing Assessment; Nursing Methodol | 2009 |
The role of methadone in cancer pain treatment--a review.
Topics: Analgesics, Opioid; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Hum | 2009 |
[Opioid rotation: a therapeutic choice in the management of refractory cancer pain].
Topics: Adult; Age Factors; Aged; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Hum | 2010 |
Review of cancer pain management in patients receiving maintenance methadone therapy.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Huma | 2011 |
Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Humans; Methadone; Neoplasms; P | 2011 |
The use of methadone for cancer pain.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Biological Availability; Child; Clinical Protocols | 2002 |
Intrathecal therapy for chronic pain.
Topics: Administration, Oral; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Disease; Hum | 2001 |
Morphine is not the only analgesic in palliative care: literature review.
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Ketamine; Methadone; Morphine; Neoplasms; Pain; Pa | 2004 |
Methadone for cancer pain.
Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Pain Measurement; Randomized Contr | 2004 |
Cancer pain management in children.
Topics: Analgesics, Opioid; Anesthesia, Conduction; Child; Chronic Disease; Fentanyl; Humans; Injections, Sp | 2004 |
Pain and terminal delirium research in the elderly.
Topics: Aged; Algorithms; Analgesics, Opioid; Anti-Infective Agents; Constipation; Delirium; Drug Interactio | 2005 |
Difficult cases in pain management: use of methadone in a multifactorial approach.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Communication; Drug Monitoring; Female; Humans; Inte | 2006 |
Methadone for treatment of cancer pain.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain | 2006 |
Practical guide to opioids and their complications in managing cancer pain. What oncologists need to know.
Topics: Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Routes; D | 2007 |
Methadone for cancer pain.
Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Pain Measurement; Randomized Contr | 2007 |
Methadone in the management of cancer pain: a review.
Topics: Humans; Methadone; Neoplasms; Pain, Intractable | 1993 |
Should people taking opioids for medical reasons be allowed to work and drive?
Topics: Accidents, Occupational; Accidents, Traffic; Analgesics, Opioid; Heroin Dependence; Humans; Long-Ter | 1996 |
An update on the clinical use of methadone for cancer pain.
Topics: Administration, Oral; Administration, Rectal; Analgesics, Opioid; Evaluation Studies as Topic; Human | 1997 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
Role of methadone in the management of pain in cancer patients.
Topics: Analgesics, Opioid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Male | 1999 |
Opioid rotation for cancer pain: rationale and clinical aspects.
Topics: Analgesics, Opioid; Fentanyl; Humans; Hydromorphone; Methadone; Morphine; Narcotics; Neoplasms; Pain | 1999 |
Opioid switch to oral methadone in cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Combined Modality Therapy; Cross-Sectional Studies; Dose-R | 2000 |
The rediscovery of methadone for cancer pain management.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain, Intractable; Prospective Studies | 2000 |
Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration.
Topics: Analgesics, Opioid; Drug Administration Routes; Drug Interactions; Humans; Methadone; Neoplasms; Pai | 2001 |
[Treatment of pain in cancer with systemically administered opioids].
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Administration Schedule; Humans; Infusion Pump | 2001 |
Strategies for the treatment of cancer pain in the new millennium.
Topics: Analgesics, Opioid; Cannabinoids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Human | 2001 |
Methadone use in cancer patients with pain: a review.
Topics: Analgesics, Opioid; Drug Interactions; Humans; Methadone; Neoplasms; Pain | 2002 |
36 trials available for methadone and Neoplasms
| Article | Year |
|---|---|
Conversion ratios for opioid switching: a pragmatic study.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Palliative Care | 2022 |
Methadone versus morphine for postoperative pain in patients undergoing surgery for gynecological cancer: A randomized controlled clinical trial.
Topics: Analgesics, Opioid; Female; Humans; Methadone; Morphine; Neoplasms; Pain Measurement; Pain, Postoper | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms | 2021 |
Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?
Topics: Aged; Analgesics, Opioid; Chromatography, High Pressure Liquid; Female; Humans; Male; Methadone; Mid | 2017 |
Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.
Topics: Aged; Ambulatory Care Facilities; Cancer Pain; Dose-Response Relationship, Drug; Female; Humans; Mal | 2016 |
The role of methadone in opioid rotation-a Polish experience.
Topics: Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; M | 2009 |
Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opi | 2010 |
The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Electrocardiog | 2010 |
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Tole | 2011 |
How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; | 2011 |
Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; | 2012 |
Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone.
Topics: Adult; Aged; Analgesia, Epidural; Dexamethasone; Drug Administration Routes; Female; Humans; Lidocai | 2013 |
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation | 2004 |
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation | 2004 |
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation | 2004 |
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Delayed-Action Preparation | 2004 |
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Drug Administratio | 2004 |
Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Chronic Disease; Cross-Over Studies; Female; | 2004 |
Rapid switching between transdermal fentanyl and methadone in cancer patients.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Methadone; Middle Age | 2005 |
Intermittent subcutaneous methadone administration in the management of cancer pain.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Injec | 2005 |
Methadone in the treatment of pain and terminal delirum in advanced cancer patients.
Topics: Aged; Analgesics, Opioid; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Analgesics, Opi | 2008 |
Combination therapy with ibuprofen and methadone for chronic cancer pain.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Emotions; Fem | 1984 |
Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine.
Topics: Adult; Analgesics; Biological Availability; Female; Humans; Injections, Intramuscular; Male; Methado | 1983 |
Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain.
Topics: Aged; Analgesics, Opioid; Capsules; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; | 1995 |
Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.
Topics: Administration, Oral; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Dose-Response Relatio | 1996 |
Opioid-sparing effect of diclofenac in cancer pain.
Topics: Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Di | 1997 |
Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.
Topics: Adult; Aged; Analgesics, Opioid; Female; Home Care Services; Humans; Male; Methadone; Middle Aged; M | 1998 |
Diclofenac does not modify methadone bioavailability in cancer patients.
Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Diclofen | 1999 |
Methadone titration in opioid-resistant cancer pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Drug Administration Schedu | 1999 |
Methadone response in advanced cancer patients with pain followed at home.
Topics: Analgesics, Opioid; Female; Home Care Services; Humans; Male; Methadone; Middle Aged; Neoplasms; Pai | 1999 |
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad | 2001 |
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad | 2001 |
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad | 2001 |
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
Topics: Administration, Oral; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methad | 2001 |
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Hydromorphone; Levorphanol; Male; Methado | 2002 |
Pain relief for cancer patients.
Topics: Chloroform; Clinical Trials as Topic; Cocaine; Dextrothyroxine; Drug Combinations; Drug Evaluation; | 1978 |
Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain.
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Infusions, | 1990 |
Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study.
Topics: Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inje | 1989 |
A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer.
Topics: Administration, Oral; Aged; Biological Availability; Clinical Trials as Topic; Dose-Response Relatio | 1986 |
A randomized study on oral administration of morphine and methadone in the treatment of cancer pain.
Topics: Administration, Oral; Clinical Trials as Topic; Female; Humans; Male; Methadone; Morphine; Neoplasms | 1986 |
144 other studies available for methadone and Neoplasms
| Article | Year |
|---|---|
Pharmacogenetics of Methadone for Pain Management in Palliative Care.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain Management; Palliative Care; Pha | 2022 |
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F | 2021 |
Association of polymorphisms in
Topics: Analgesics, Opioid; beta-Arrestin 2; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Polymorphism, | 2022 |
Methadone as First-line Opioid for the Management of Cancer Pain.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Neoplasms; Pain; Prospective Studies | 2022 |
Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Cancer Pain; Consensus; Female; Humans; Male; Me | 2022 |
Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Death; G Protein-Coupled Inwardly-Rectifying Potassium Chan | 2022 |
Methadone switching for refractory cancer pain.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Humans; Methadone; Neoplasms; Retrospective Stud | 2022 |
Two Patients Experience Same-Day Analgesic Effect of Methadone on Trigeminal Neuralgia Secondary to Malignancy: A Case Report.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Quality of Life; Treatment Outcome; Trigeminal Neu | 2023 |
Switching to Intravenous Methadone in Advanced Cancer Patients: A Retrospective Analysis.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Retrospective Studies | 2023 |
[Drug therapy for cancer-related pain-evidence regarding hydromorphone, oxycodone, and methadone : Presentation and summary of three Cochrane reviews].
Topics: Analgesics, Opioid; Cancer Pain; Humans; Hydromorphone; Methadone; Neoplasms; Oxycodone | 2023 |
A better interpretation of data regarding the opioid switching to methadone.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain Measurement; Palliative Care | 2023 |
Reply to "A better interpretation of data regarding the opioid switching to methadone".
Topics: Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Humans; Methadone; Neoplasms; Pai | 2023 |
Juggling Two Full-Time Jobs - Methadone Clinic Engagement and Cancer Care.
Topics: Humans; Methadone; Neoplasms; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care.
Topics: Analgesics, Opioid; Cancer Pain; Death; Humans; Methadone; Neoplasms; Palliative Care; Sweden | 2020 |
Methadone rotation for cancer pain: an observational study.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Methadone; Morphine; Neoplasms; Neuralgia | 2022 |
The role of methadone in cancer-induced bone pain: a retrospective cohort study.
Topics: Aged; Analgesics, Opioid; Bone and Bones; Cancer Pain; Female; Humans; Male; Methadone; Neoplasms; P | 2021 |
Methadone for Cancer Pain in Pediatric End-of-Life Care.
Topics: Analgesics, Opioid; Cancer Pain; Child; Drug Tolerance; Humans; Methadone; Neoplasms; Retrospective | 2021 |
A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children.
Topics: Adolescent; Aftercare; Analgesics, Opioid; Child; Child, Preschool; Female; Hospitalization; Humans; | 2021 |
Combination therapy with methadone and duloxetine for cancer-related pain: a retrospective study.
Topics: Cancer Pain; Duloxetine Hydrochloride; Humans; Methadone; Neoplasms; Retrospective Studies; Treatmen | 2021 |
First-line methadone for cancer pain: titration time analysis.
Topics: Analgesics, Opioid; Breakthrough Pain; Cancer Pain; Dose-Response Relationship, Drug; Humans; Methad | 2021 |
Antinociceptive synergism upon the joint use of methadone and Phα1β in a model of cancer-related pain in C57BL/6J mice.
Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Cancer Pain; Dr | 2021 |
Assistance of a Palliative Care Certified Nurse in the Alleviation of Refractory Cancer Pain by Switching Opioids to Oral Methadone in a Japanese Outpatient Setting.
Topics: Analgesics, Opioid; Cancer Pain; Humans; Japan; Methadone; Neoplasms; Outpatients; Pain, Intractable | 2021 |
The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain.
Topics: Adolescent; Adult; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Dose-Response Relations | 2017 |
Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report.
Topics: Analgesics, Opioid; Humans; Male; Methadone; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Pain; | 2017 |
Response to the Article "Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids".
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain Management; Rotation | 2017 |
Intravenous methadone in a patient with advanced cancer.
Topics: Administration, Intravenous; Analgesics, Opioid; Cancer Pain; Humans; Male; Methadone; Middle Aged; | 2019 |
Evaluation of QTc Interval Prolongation Among Patients With Cancer Using Enteral Methadone.
Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Female; Humans; Long | 2019 |
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
Topics: Adult; Algorithms; Analgesics; Child; Chronic Pain; Clinical Decision-Making; Humans; Ketamine; Medi | 2019 |
QT Interval Prolongation in the Pediatric Oncologic Population on Methadone.
Topics: Adolescent; Adult; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Female; Follow-Up Studi | 2020 |
Dying To Access Methadone.
Topics: Adult; Analgesics, Opioid; Government Regulation; Heroin Dependence; Hospice Care; Humans; Male; Met | 2019 |
Changes of QTc interval after opioid switching to oral methadone.
Topics: Aged; Analgesics, Opioid; Electrocardiography; Female; Humans; Linear Models; Long QT Syndrome; Male | 2013 |
Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle | 2013 |
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Breakthrough Pain; Constipation; Female; Fentanyl; | 2014 |
What is your gut feeling about opioid rotation?
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Biological Availability; Delaye | 2015 |
Extreme doses of intravenous methadone for severe pain in two children with cancer.
Topics: Adolescent; Analgesics, Opioid; Child; Female; Humans; Injections, Intravenous; Male; Methadone; Neo | 2015 |
Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.
Topics: Analgesics, Opioid; Cancer Pain; Developing Countries; Female; Humans; Male; Methadone; Middle Aged; | 2016 |
Methadone as a Coanalgesic for Palliative Care Cancer Patients.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain; Palliative Care | 2016 |
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain | 2016 |
Overall Survival among Cancer Patients Undergoing Opioid Rotation to Methadone Compared to Other Opioids.
Topics: Analgesics, Opioid; Female; Humans; Kaplan-Meier Estimate; Male; Methadone; Middle Aged; Neoplasms; | 2017 |
[Use of methadone for support of oncological treatment? : Statement of the working group on tumor pain of the German Pain Society].
Topics: Analgesics, Opioid; Antineoplastic Agents; Brain Neoplasms; Cancer Pain; Drug Approval; Drug Resista | 2017 |
Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Case-Control Studies; Dose-Response | 2017 |
Opioid-induced pain.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; | 2008 |
Myoclonus associated with high-dose parenteral methadone.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Hospice Care; Humans; Male; Methadone; | 2008 |
[Analgesics and palliative care].
Topics: Analgesics; Analgesics, Opioid; Fentanyl; Humans; Methadone; Morphine; Neoplasms; Pain; Palliative C | 2008 |
Switching from methadone to a different opioid: what is the equianalgesic dose ratio?
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle | 2008 |
Conversion from parenteral to oral methadone.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Biological Availability; Dose-Res | 2008 |
Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Dose-Response Relationship, Drug | 2009 |
Cauda equina syndrome and decreasing opioid requirements.
Topics: Analgesics, Opioid; Humans; Methadone; Narcotic Antagonists; Neoplasms; Polyradiculopathy; Receptors | 2009 |
Methadone initiation and rotation in the outpatient setting for patients with cancer pain.
Topics: Ambulatory Care; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methadone; | 2010 |
Recent advances in the treatment of cancer pain.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain, Intractable; Palliative Care | 2010 |
The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Long QT Syndrome; M | 2010 |
A formal feasibility study of sublingual methadone for breakthrough cancer pain.
Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Alberta; Analgesics, Opioid; Drug Monito | 2010 |
Neostigmine for the treatment of gastrointestinal atony: a report of one case.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Humans; Injections, Subcutaneous; Methadone; Neoplas | 2011 |
Methadone maintenance and cancer risk: an Israeli case registry study.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Cohort Studies; Databases, Factual; Female; Humans; Isr | 2011 |
Switching from oxycodone to methadone in advanced cancer patients.
Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle | 2012 |
Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Opioid; Delayed-Action Preparati | 2008 |
Practicability, safety, and efficacy of a "German model" for opioid conversion to oral levo-methadone.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Substitut | 2012 |
Stop and go strategy for opioid switching requires flexibility.
Topics: Analgesics, Opioid; Drug Substitution; Female; Humans; Male; Methadone; Morphine; Neoplasms; Oxycodo | 2012 |
Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Ne | 2012 |
Switching from methadone to tapentadol for cancer pain.
Topics: Aged; Analgesics, Opioid; Female; Humans; Methadone; Multiple Myeloma; Neoplasms; Pain; Phenols; Tap | 2012 |
Three weeks from diagnosis to death: the chaotic journey of a long-term methadone maintenance patient with terminal cancer.
Topics: Australia; Fatal Outcome; Humans; Male; Methadone; Middle Aged; Neoplasms; Opioid-Related Disorders; | 2013 |
Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Neoplasms | 2013 |
Opioid "holiday" following antagonist supported detoxification during general anesthesia improves opioid agonist response in a cancer patient with opioid addiction.
Topics: Analgesia, Epidural; Analgesics, Opioid; Anesthesia, General; Anesthetics, Local; Bone Neoplasms; Bu | 2003 |
Opioid plasma concentration during switching from morphine to methadone: preliminary data.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administratio | 2003 |
An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population.
Topics: Administration, Oral; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; China; Drug Ad | 2003 |
Methadone and the hospice patient: prescribing trends in the home-care setting.
Topics: Analgesics, Opioid; Drug Prescriptions; Drug Utilization; Female; Home Care Services; Hospice Care; | 2003 |
A CLINICAL TRIAL OF A MIXTURE OF LEVORPHANOL AND LEVALLORPHAN AS AN ORAL ANALEGESIC.
Topics: Drug Therapy; Humans; Levallorphan; Levorphanol; Methadone; Neoplasms; Osteoarthritis; Pain; Substan | 1964 |
Switching to methadone: 'ad libitum' or fixed dose ratio?
Topics: Analgesics, Opioid; Chronic Disease; Humans; Methadone; Morphine; Neoplasms; Pain; Patient Satisfact | 2004 |
Methadone: an orphan drug?
Topics: Analgesics, Opioid; Fees, Pharmaceutical; Humans; Methadone; Neoplasms; Orphan Drug Production; Pain | 2004 |
Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Electrocardiography; Heart Rate; Humans; Methadone; Neopla | 2004 |
Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Hydromorphone; Methadone; Midd | 2005 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chromatography, High Pressure Liquid; Female; Ha | 2006 |
Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study.
Topics: Administration, Sublingual; Aged; Alberta; Analgesics, Opioid; Clinical Protocols; Drug Monitoring; | 2007 |
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Drug Administration Schedule; Female; Fe | 2007 |
Subcutaneous methadone--an issue revisited.
Topics: Aged; Analgesics, Opioid; Humans; Injections, Subcutaneous; Low Back Pain; Male; Methadone; Middle A | 2007 |
Methadone analgesia for children with advanced cancer.
Topics: Adolescent; Analgesia; Analgesics, Opioid; Child; Child, Preschool; Drug Evaluation; Drug-Related Si | 2008 |
Pharmaceutics: choice of a strong analgesic for cancer patients.
Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain, Intractable | 1982 |
Patient-controlled dose regimen of methadone for chronic cancer pain.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle | 1981 |
[Peroral analgetic treatment with a methadone mixture in terminal cancer patients].
Topics: Administration, Oral; Aged; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; Pain; Palliativ | 1981 |
[Long-lasting pain relief with rectal methadone therapy].
Topics: Aged; Female; Humans; Male; Methadone; Neoplasms; Pain; Palliative Care; Rectum; Suppositories | 1983 |
Methadone and intravenous morphine requirements. Treatment of pain due to advanced cancer.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain, In | 1983 |
Pharmacist intervention in methadone administration to cancer patients with chronic pain.
Topics: Adolescent; Adult; Aged; Chronic Disease; Humans; Methadone; Middle Aged; Neoplasms; Pain; Pharmacis | 1983 |
Patient-controlled dose regimen of methadone for chronic cancer pain.
Topics: Analgesics; Humans; Methadone; Neoplasms | 1981 |
[Morphine and methadone in severe cancer pain--new pharmacokinetic bases for optimal therapy].
Topics: Chronic Disease; Humans; Kinetics; Methadone; Morphine; Neoplasms; Pain | 1983 |
Methadone for pain relief in disseminated malignant disease.
Topics: Female; Humans; Male; Methadone; Neoplasm Metastasis; Neoplasms; Pain, Intractable; Terminal Care | 1980 |
How to use methadone. A handbook for patients and families.
Topics: Humans; Methadone; Neoplasms; Pain; Patient Education as Topic; Self Administration | 1981 |
How to use methadone for the cancer patient's pain.
Topics: Dose-Response Relationship, Drug; Humans; Methadone; Neoplasms; Pain, Intractable | 1980 |
Nursing care in childhood cancer: methadone.
Topics: Adolescent; Analgesics; Child; Child, Preschool; Humans; Infant; Liver; Methadone; Neoplasms; Pain, | 1982 |
Clinical evaluation of oral methadone in treatment of cancer pain.
Topics: Administration, Oral; Adult; Aged; Female; Half-Life; Humans; Male; Methadone; Middle Aged; Neoplasm | 1982 |
Clinical evaluation of combined treatment with methadone and psychotropic drugs in cancer patients.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Methadone; Middle Aged; M | 1982 |
Pharmacokinetic basis for optimal methadone treatment of pain in cancer patients.
Topics: Adult; Aged; Female; Half-Life; Humans; Kinetics; Male; Methadone; Middle Aged; Models, Biological; | 1982 |
Oral methadone for relief of chronic pain from cancer.
Topics: Chronic Disease; Humans; Methadone; Morphine; Neoplasms; Pain, Intractable | 1982 |
Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; Orosomucoid; Serum | 1982 |
Experience with dipipanone elixir in the management of cancer related pain--case study.
Topics: Aged; Aged, 80 and over; Analgesics; Dosage Forms; Female; Humans; Male; Methadone; Middle Aged; Neo | 1994 |
Successful use of methadone in nociceptive cancer pain unresponsive to morphine.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methado | 1994 |
Respiratory depression in a patient receiving oral methadone for cancer pain.
Topics: Administration, Oral; Female; Humans; Methadone; Middle Aged; Neoplasms; Pain; Respiration Disorders | 1995 |
Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics.
Topics: Adolescent; Adult; Analgesics; Child; Drug Tolerance; Female; Humans; Male; Methadone; Middle Aged; | 1993 |
Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists.
Topics: Adult; Aged; Analgesics, Opioid; Child; Delayed-Action Preparations; Female; Humans; Hyperalgesia; M | 1994 |
CSF neuropeptides in cancer pain: effects of spinal opioid therapy.
Topics: Aged; Bupivacaine; Female; Humans; Injections, Epidural; Injections, Spinal; Male; Methadone; Middle | 1993 |
Methadone for treatment of cancer pain.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Humans; Methadone; Neoplasms; Pain, Intractable | 1996 |
Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations.
Topics: Adult; Aged; Analgesics, Opioid; Capsules; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; | 1996 |
Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Opioid; Cohort Studies; Dose-Response Rel | 1996 |
Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Neopla | 1996 |
Pharmacologic treatment of cancer pain.
Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain; Therapeutic Equivalency | 1997 |
Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Dose-Response Relationship, Drug; Humans; Infusio | 1997 |
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Admini | 1998 |
Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; | 1998 |
Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Humans; Ketamine; Methadone; N-Methylaspartate; Neopl | 1998 |
Comment on Manfredi et al.,Pain, 70 (1997) 199-101.
Topics: Analgesics, Opioid; Humans; Hydromorphone; Injections, Intravenous; Methadone; Morphine; Neoplasms; | 1998 |
Methadone in cancer pain management: individualize dose and titrate to effect.
Topics: Analgesics, Opioid; Humans; Methadone; Morphine; Neoplasms; Pain Management | 1998 |
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re | 1998 |
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re | 1998 |
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re | 1998 |
Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?
Topics: Administration, Oral; Aged; Analgesia; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Re | 1998 |
Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases.
Topics: Administration, Oral; Analgesia, Patient-Controlled; Analgesics, Opioid; Burns; Child; Child, Presch | 1998 |
Opioid substitution to reduce adverse effects in cancer pain management.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hospice Care; Humans; Male; Medical A | 1999 |
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; | 1999 |
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; | 1999 |
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; | 1999 |
Rapid switching from morphine to methadone in cancer patients with poor response to morphine.
Topics: Aged; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; | 1999 |
Methadone: outpatient titration and monitoring strategies in cancer patients.
Topics: Analgesics, Opioid; Cohort Studies; Humans; Methadone; Monitoring, Physiologic; Neoplasms; Outpatien | 1999 |
Pain management in patients with advanced cancer.
Topics: Analgesics, Opioid; Humans; Methadone; Neoplasms; Pain | 2000 |
Respiratory depression during methadone rotation in a patient with advanced cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Humans; Lung Neoplasms; Male; Methadone; Neoplasms; Pai | 2000 |
[Treating hospitalized children in severe pain with oral methadone].
Topics: Administration, Oral; Analgesics, Opioid; Burns; Child; Child, Hospitalized; Child, Preschool; Femal | 1998 |
The merits of methadone.
Topics: Adult; Analgesics, Opioid; Child; Child, Preschool; Chronic Disease; Humans; Methadone; Morphine; Ne | 2000 |
Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy.
Topics: Adult; Analgesia; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Male; Methadone; | 2001 |
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Topics: Administration, Oral; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Administration Schedule; F | 2001 |
The rediscovery of methadone for cancer pain management.
Topics: Humans; Methadone; Neoplasms; Pain, Intractable | 2001 |
Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Administration Schedule; Female | 2001 |
Methadone: the question or the answer for US opioid therapy and pharmaco-economics?
Topics: Analgesics, Opioid; Humans; Methadone; Models, Theoretical; Neoplasms; Opioid-Related Disorders; Pai | 2001 |
Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Humans; Infusions, Intravenous; Male; Meth | 2002 |
[Strong opiate analgesics for cancer pain].
Topics: Humans; Methadone; Morphine; Narcotics; Neoplasms; Palliative Care | 1979 |
Cancer patients dying at home. The last 24 hours.
Topics: Attitude to Death; Death; Home Care Services; Humans; Methadone; Methotrimeprazine; Neoplasms; Palli | 1979 |
Important clinical pharmacologic considerations in the use of methadone in cancer patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle Aged; Neoplasms; | 1979 |
Death rates and causes of death among opioid addicts in community drug treatment programs during 1970-1973.
Topics: Adult; Age Factors; Black or African American; Cardiovascular Diseases; Community Mental Health Serv | 1975 |
Population-based study of malignancies and HIV infection among injecting drug users in a New York City methadone treatment program, 1985-1991.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Female; HIV Infections; Humans; Incidence; Male; Me | 1992 |
Continuous epidural methadone treatment for cancer pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Chronic Disease; Female; Humans; Ma | 1991 |
Treatment of severe cancer pain by continuous infusion of subcutaneous opioids.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Methadone; Middle A | 1991 |
Local toxicity with subcutaneous methadone. Experience of two centers.
Topics: Adult; Erythema; Female; Humans; Injections, Subcutaneous; Male; Methadone; Middle Aged; Neoplasms; | 1991 |
Epidural and intrathecal opiates: cerebrospinal fluid and plasma profiles in patients with chronic cancer pain.
Topics: Adult; Aged; beta-Endorphin; Drug Evaluation; Endorphins; Epidural Space; Female; Half-Life; Humans; | 1985 |
I.v. infusion of opioids for cancer pain: clinical review and guidelines for use.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Hum | 1986 |
Exceptionally high narcotic analgesic requirements in a terminally ill cancer patient.
Topics: Adult; Analgesics, Opioid; Combined Modality Therapy; Drug Tolerance; Female; Humans; Hydromorphone; | 1986 |
In vivo carcinogenesis assay of L-alpha-acetylmethadol.HCl in rodents.
Topics: Animals; Carcinogenicity Tests; Eating; Female; Lethal Dose 50; Male; Methadone; Methadyl Acetate; M | 1988 |
In vivo carcinogenesis assay of DL-methadone.HCl in rodents.
Topics: Animals; Body Weight; Carcinogenicity Tests; Eating; Female; Lethal Dose 50; Male; Methadone; Mice; | 1988 |
[3-step pharmacologic treatment of pain in cancer. Preliminary experience in Chile].
Topics: Acetaminophen; Adult; Analgesics; Chile; Codeine; Drug Administration Schedule; Female; Follow-Up St | 1988 |
Estimation of methadone clearance: application in the management of cancer pain.
Topics: Blood Specimen Collection; Forecasting; Humans; Methadone; Models, Biological; Neoplasms; Pain Manag | 1988 |
Cancer pain control with a combination of methadone, amitriptyline, and non-narcotic analgesic therapy: a case series analysis.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics; Drug Therapy, Combination; Female; Humans; Male; | 1987 |
Surgical management of pain in cancer of the head and neck.
Topics: Alcohols; Autonomic Nerve Block; Carbamazepine; Chlorpromazine; Cranial Nerves; Gastrostomy; Head; H | 1973 |
A gas-liquid chromatographic method for the quantitative determination of methadone in human plasma and urine.
Topics: Chromatography, Gas; Humans; Methadone; Methods; Neoplasms; Pain; Time Factors | 1972 |
A look at narcotic and nonnarcotic analgesics.
Topics: Analgesics; Dextropropoxyphene; Drug Antagonism; Drug Combinations; Drug Prescriptions; Drug Toleran | 1971 |